Thailand at a glance
- Population
- 71.6 million 2025
- Life expectancy at birth
- 76.6 years, 2024
- People aged 65 and over
- 16.0 % of people, 2025
- Health spending per person
- 327 US$ per person, 2023
- Doctors
- 0.54 per 1,000 people, 2021
Updated
Reviewed by Vidhi Upadhyay
Thailand RSV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$8.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $4.2 Mn | — | — |
| 2025 (base) | $4.7 Mn | +$0.5 Mn | — |
| 2026 (forecast) | $5.2 Mn | +$0.6 Mn | +12.3% |
| 2027 (forecast) | $5.9 Mn | +$0.6 Mn | +26.1% |
| 2028 (forecast) | $6.6 Mn | +$0.7 Mn | +41.6% |
| 2029 (forecast) | $7.4 Mn | +$0.8 Mn | +59% |
| 2030 (forecast) | $8.3 Mn | +$0.9 Mn | +78.6% |
| 2031 (forecast) | $9.4 Mn | +$1.0 Mn | +100.6% |
| 2032 (forecast) | $10.5 Mn | +$1.2 Mn | +125.2% |
| 2033 (forecast) | $11.8 Mn | +$1.3 Mn | +153% |
| 2034 (forecast) | $13.3 Mn | +$1.5 Mn | +184.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $4.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $13.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 12.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, age and end user (see all) |
| Key players | GSK PLC, Pfizer Inc., Moderna, Sanofi, AstraZeneca (see all) |
| Regulator in Thailand | Thai FDASource: Thai Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
RSV vaccines protect older adults, pregnant women (for their babies) and infants against respiratory syncytial virus, a common cause of serious chest infections.
Key segments of the RSV Vaccines market include product (Older Adult Vaccines, Maternal Vaccines and Infant Monoclonal Antibodies) and age (Infants, Older Adults and Pregnant Women).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.
New vaccines, rapid tests and public-private funding for neglected diseases give the RSV Vaccines market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the RSV Vaccines market.
The RSV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines need registration with the Thai Food and Drug Administration (Thai FDA).[1] The Universal Coverage Scheme, run by the National Health Security Office (NHSO), covers people outside the social security and civil servant schemes.[2]
[1] Thai Food and Drug Administration. Checked 14 Nov 2026.
[2] National Health Security Office. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RSV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Thailand.
What doctors and scientists are doing in RSV Vaccines right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
Thailand · 2 shared keywords
Thailand · 1 shared keyword
Thailand
Thailand
Thailand
Thailand
Medical Devices · Thailand
Medical Devices · Thailand
Medical Devices · Thailand
Medical Devices · Thailand
OTC & Nutraceuticals · Thailand
Medical Devices · Thailand